Walleye Capital LLC Makes New $5.40 Million Investment in Capricor Therapeutics, Inc. $CAPR

Walleye Capital LLC purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 177,543 shares of the biotechnology company’s stock, valued at approximately $5,397,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter valued at approximately $1,039,000. Moody Aldrich Partners LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $6,025,000. UBS Group AG lifted its position in shares of Capricor Therapeutics by 91.0% in the 4th quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock worth $6,875,000 after purchasing an additional 113,499 shares during the period. HBK Sorce Advisory LLC boosted its stake in shares of Capricor Therapeutics by 19.4% in the 4th quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock valued at $5,879,000 after purchasing an additional 33,128 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 4.4%

Shares of CAPR stock opened at $18.91 on Thursday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -8.15 and a beta of 0.42. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a 50 day moving average of $25.67 and a 200-day moving average of $27.58.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Analysts anticipate that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. LADENBURG THALM/SH SH raised shares of Capricor Therapeutics to a “strong-buy” rating in a research report on Thursday, June 25th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Finally, Roth Capital reissued a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.67.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 50,000 shares of company stock valued at $1,551,658 in the last ninety days. Company insiders own 9.20% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.